The drug inhibits intracellular raf kinases (CRAF and BRAF) as well as cell surface kinase receptors such as Fms-like tyrosine kinase receptor 3 (Flt-3), c-kit, Ret, vascular endothelial growth factor (VEGF)-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-beta).5,6 One of the most common adverse effects of sorafenib is upper and lower GI distress which manifests as reflux or dyspepsia and epigastric pain, causing appetite loss, weight loss, and fatigue.7,8. Here, PDGFRB is linked to dyspepsia.